Hypertension and arterial stiffness

Lattanzi, Simona; Brigo, Francesco; Silvestrini, Mauro

doi:10.1111/jch.13690

Cited by 5 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature survey was carried out with emphasis on diseases reported to be associated with vascular stiffening: congenital heart disease (CHD) [ 19 ], thoracic aortic aneurysm (TAA) [ 20 , 21 ], and hypertension [ 17 , 18 ]. We utilized the PubMed database, as well as Google Scholar, in order to select the source literature containing candidate genes or loci with mutations to be analyzed regarding each disease.…”

Section: Methodsmentioning

confidence: 99%

“…Arterial stiffening, an independent predictor of cardiovascular morbidity and mortality, plays an important role in cardiovascular diseases (CVDs) [ 15 , 16 ], including hypertension [ 17 , 18 ], congenital heart disease (CHD) [ 19 ], and thoracic aortic aneurysms (TAA) [ 20 , 21 ]. Given the multigenic causes of these conditions, elucidation of the genetic characteristics or factors impacting high mutation rates might reduce the burden of high mortalities [ 22 ] in these CVDs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Factors Associated with Mutations: Their Matching Rates to Cardiovascular and Neurological Diseases

Lucas

McKnight

Raines

et al. 2021

IJMS

View full text Add to dashboard Cite

Monogenic hypertension is rare and caused by genetic mutations, but whether factors associated with mutations are disease-specific remains uncertain. Given two factors associated with high mutation rates, we tested how many previously known genes match with (i) proximity to telomeres or (ii) high adenine and thymine content in cardiovascular diseases (CVDs) related to vascular stiffening. We extracted genomic information using a genome data viewer. In human chromosomes, 64 of 79 genetic loci involving >25 rare mutations and single nucleotide polymorphisms satisfied (i) or (ii), resulting in an 81% matching rate. However, this high matching rate was no longer observed as we checked the two factors in genes associated with essential hypertension (EH), thoracic aortic aneurysm (TAA), and congenital heart disease (CHD), resulting in matching rates of 53%, 70%, and 75%, respectively. A matching of telomere proximity or high adenine and thymine content projects the list of loci involving rare mutations of monogenic hypertension better than those of other CVDs, likely due to adoption of rigorous criteria for true-positive signals. Our data suggest that the factor–disease matching rate is an accurate tool that can explain deleterious mutations of monogenic hypertension at a >80% match—unlike the relatively lower matching rates found in human genes of EH, TAA, CHD, and familial Parkinson’s disease.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Factors Associated with Mutations: Their Matching Rates to Cardiovascular and Neurological Diseases

Lucas

McKnight

Raines

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

Sex-specific cardiac and vascular responses to hypertension in Chinese populations without overt cardiovascular diseases

Liu

Shen

et al. 2020

Postgraduate Medicine

View full text Add to dashboard Cite

Effects of vitamin C supplementation on essential hypertension

2020

View full text Add to dashboard Cite

Background: Vitamin C as a supplement to treat hypertension has been proposed. However, it remains controversial whether vitamin C can improve blood pressure in patients with primary hypertension. Objectives: To analyze the effect of vitamin C (VitC) supplementation on systolic (SBP) and diastolic (DBP) blood pressure in patients with essential hypertension. Methods: We searched the Chinese Knowledge Infrastructure, VIP Database for Chinese Technical Periodicals, WANFANG Data, Cochrane Library, National Library of Medicine's PubMed, EMBASE, and other databases until June 2019. Eight RCTs involving 614 participants were analyzed. SBP and DBP before and after VitC supplementation were compared between the intervention and control groups. The risk of bias of individual studies was assessed using the Cochrane Collaboration risk of bias tool. Two reviewers selected studies independently of each other. The Cochrane Collaboration Review Manager 5.3 was used to perform the meta-analysis. Results: There was a significant difference in the change of SBP (weighted mean difference [WMD] = −4.09; 95% confidence interval [CI] −5.56, −2.62; P < .001) and DBP (WMD = −2.30; 95% CI −4.27, −.331; P = .02) between the groups. Further, there was a significant difference in the SBP (WMD = -3.75, 95% CI -6.24, -1.26, P = .003) and DBP (WMD = −3.29, 95% CI −5.98, −.60, P = .02) for the subgroup with an age ≥60 years and that with ≥35 participants. In the subgroup analysis, result for SBP with a study duration ≥6 weeks was statistically significant different (WMD = −4.77; 95% CI −6.46, −3.08; P < .001). For an intervention dose of VitC ≥500 mg daily, SBP was statistically significant (WMD = −5.01; 95% CI −8.55, −1.48; P = .005). Conclusion: VitC supplementation resulted in a significant reduction of blood pressure in patients with essential hypertension.

show abstract

Hypertension and arterial stiffness

Cited by 5 publications

References 43 publications

Factors Associated with Mutations: Their Matching Rates to Cardiovascular and Neurological Diseases

Factors Associated with Mutations: Their Matching Rates to Cardiovascular and Neurological Diseases

Sex-specific cardiac and vascular responses to hypertension in Chinese populations without overt cardiovascular diseases

Effects of vitamin C supplementation on essential hypertension

Contact Info

Product

Resources

About